Taysha
efficacy outperformed unregulated in mouse survival study | Taysha
Company
Deck Type
IPO
Sector
Industry
Deck date
September 2020
Slide
36 of 66
Related slides by other companies
Aeglea BioTherapeutics
Investor Presentation
July 2023
is rapidly developing combination products given clinical evidence of substantial efficacy enhancement | Aeglea BioTherapeutics
Chimerix
Investor Presentation
August 2023
agonist distinct molecular target and efficacy profile relative to efficacy in preclinical models of advanced cancers tox studies complete potential to advance to partnerships established for early stage clinical trials with brown university and cancer center preclinical studies are ongoing to evaluate additional oncology indications and predictive for for clinical development pancreatic cancer model shows the potential of | Chimerix
Aeglea BioTherapeutics
Investor Presentation
September 2023
is rapidly developing combination products given clinical evidence of substantial efficacy enhancement | Aeglea BioTherapeutics
Aeglea BioTherapeutics
Mergers and Acquisitions
June 2023
is rapidly developing combination products given clinical evidence of substantial efficacy enhancement | Aeglea BioTherapeutics
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io